Search
Selected Filters
Filter Results
Displaying 31–40 of 135 news results
-
May 12, 2022
Opus Genetics Appoints Jennifer Hunt Chief Development Officer
Biopharma clinical development veteran to propel Opus’ AAV-based gene therapies for inherited retinal diseases toward patients.
-
May 12, 2022
Foundation Fighting Blindness to Host VISIONS 2022 Conference
The national conference will be held on June 17–18, featuring sessions with the latest research advancements, practical adapting and thriving, and an opportunity to connect with the blind and low vision community.
-
May 10, 2022
The Foundation Fighting Blindness, the world’s leading organization committed to finding treatments and cures for retinal degenerative diseases, will host an online continuing medical education (CME and COPE) course on inherited retinal disease gene therapies on Thursday, June 9, 2022, at 7:00 p.m. EDT.
-
Apr 22, 2022
Foundation Summit Highlights Robust Growth in Commercial Development for Retinal Disease Therapies
The Foundation’s Investing in Cures Summit (ICS), held on April 2, 2022, in Half Moon Bay, California, convened 175 researchers, industry executives, and constituents to present and discuss the expanding and accelerating commercial development of emerging therapies for retinal degenerative diseases.
-
Mar 8, 2022
Trial recruitment is enabled by the Foundation Fighting Blindness’ patient registry, My Retina Tracker® Registry, which includes genetic and vision information for more than 20,000 people with inherited retinal diseases.
-
Mar 3, 2022
Clearside Biomedical Appoints Benjamin R. Yerxa, Ph.D. to its Board of Directors
Industry Veteran Brings Broad Ophthalmology Research & Development Expertise.
-
Feb 23, 2022
The March 6th virtual event will raise awareness and fund research leading to treatments and cures for blinding retinal diseases.
-
Jan 27, 2022
Commitment to expand translational research acceleration program and fund career development award.
-
Jan 19, 2022
Foundation Fighting Blindness Promotes Jason Menzo to President and Chief Operating Officer
Noteworthy Foundation executive increases role within organization.
-
Jan 6, 2022
RD Fund Announces Series B Financing Behind SalioGen Therapeutics
Investment in new portfolio company furthering genetic medicine approaches for individuals affected by retinal degenerative diseases.